Shanghai, China, September 11, 2026
Accro Bioscience has announced that its investigational AC-101 tablets have been included in the “Caring Plan-Extension” Pilot Program of the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). The inclusion represents an important regulatory milestone for the development of AC-101 and highlights continued efforts to accelerate the availability of potential treatments for patients affected by rare diseases. Through the pilot program, Accro Bioscience will work within a regulatory framework designed to facilitate drug development for diseases with significant unmet medical needs. The company said the recognition demonstrates the potential value of AC-101 in addressing an important rare-disease treatment gap and provides additional support for its clinical development strategy.
AC-101 Included in NMPA Rare Disease Pilot Program
The inclusion of AC-101 tablets in the NMPA CDE’s Caring Plan-Extension Pilot Program is significant because regulatory programs focused on rare diseases can help developers address challenges associated with limited patient populations, specialized clinical requirements and unmet medical needs. For Accro Bioscience, participation in the pilot program provides an opportunity to engage more closely with Chinese regulatory authorities during the development of AC-101. The initiative is intended to encourage the efficient development of therapies for rare diseases while maintaining appropriate standards for drug quality, safety and efficacy. Accro Bioscience said the program provides additional regulatory support as the company advances its investigational therapy through the development process. The regulatory recognition also reflects the growing emphasis in China on accelerating innovative treatments for rare and difficult-to-treat diseases. Drug developers working in these areas often face challenges in recruiting sufficient numbers of patients for clinical studies because individual rare diseases can affect relatively small populations. Regulatory mechanisms that encourage early communication between sponsors and authorities can potentially help companies develop more appropriate clinical and regulatory strategies while continuing to meet requirements for evidence generation.
Rare Disease Development and Unmet Medical Needs
AC-101 is being developed as an investigational pharmaceutical therapy for a rare disease, placing the program within the broader field of innovative drug development. Accro Bioscience’s participation in the Caring Plan-Extension Pilot Program underscores the importance of developing new treatment options for patients who may have limited therapeutic alternatives. The program’s focus on rare-disease medicines aligns with increasing efforts across the global biopharmaceutical industry to advance treatments for conditions that have historically received less attention because of their small patient populations. For patients and healthcare professionals, progress in rare-disease drug development can be particularly important because many rare disorders have substantial impacts on quality of life and may lack effective approved therapies. Development programs such as AC-101 therefore require careful evaluation through appropriate clinical, regulatory and scientific pathways. Inclusion in a regulatory pilot program does not itself mean that AC-101 has been approved or established as an effective treatment, but it represents an important step in the company’s ongoing development activities.
Advertisement
Regulatory Milestone Supports Future Clinical Development
Accro Bioscience views the NMPA CDE inclusion as a meaningful milestone for AC-101 development and its broader commitment to rare-disease therapeutics. The company is expected to continue working with regulatory authorities as it progresses the program and generates additional evidence required for future development decisions. The pilot-program recognition may help establish a more coordinated regulatory pathway as Accro Bioscience advances its plans for the investigational medicine. The announcement also highlights the increasingly important role of regulatory innovation in rare-disease drug development. As pharmaceutical companies develop therapies for smaller patient populations, regulatory agencies are exploring mechanisms that can facilitate communication and development planning while preserving rigorous standards for medicines. Accro Bioscience’s inclusion in the NMPA CDE initiative therefore represents not only a company-specific milestone but also part of the broader evolution of China’s rare-disease pharmaceutical development landscape.For cGxP.wire readers, the announcement provides insight into how regulatory programs, rare-disease research and pharmaceutical innovation are coming together to support the development of potential new therapies. The continued progress of AC-101 will be an area to watch as Accro Bioscience advances the program toward subsequent clinical and regulatory milestones.
Source: Accro Bioscience press release
